Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 15
Tirzepatide and Work: Survey Findings
A survey of 518 US employees starting tirzepatide found strong support for obesity-drug coverage, but it did not measure treatment effects.
Tirzepatide and Exercise Anaphylaxis
A case report links tirzepatide with exercise-induced anaphylaxis in one patient, with no recurrence after the medicine was stopped.
Tirzepatide in pasireotide hyperglycemia
A new case report found improved glucose measures after tirzepatide in one patient with pasireotide-related hyperglycemia. Here is what it can and cannot show.
Foundayo's $98 million launch quarter
Lilly reported $98 million in Q2 revenue for oral GLP-1 Foundayo. The filing shows an early launch, not proof that the medicine disappointed.
GLP-1 Drugs and Skin Disease Evidence
A 2026 review finds the strongest GLP-1 skin evidence in psoriasis, while most other dermatology uses remain observational.
Do GLP-1 Drugs Affect Muscle and Bone?
A 2026 meta-analysis found a low-certainty lean-mass signal with GLP-1 drugs, but no adjusted effect on bone or joint outcomes.
GLP-1 Weight Loss Depended on AgRP Neurons
A 2026 mouse study found that disrupting AgRP neurons weakened the full weight-lowering response to GLP-1 receptor agonists in females.
How GLP-1 Analogs Are Engineered
A 2026 review explains how GLP-1 analogs use sequence changes, peptide shape and lipidation to resist breakdown and last longer.
Incretins and MASLD: What 24 Trials Found
A 2026 review found better liver enzymes and MASH resolution with incretin therapies, but fibrosis regression remained uncertain.
Knee Surgery: Semaglutide vs Tirzepatide
A matched US study found similar short-term knee-replacement outcomes in people with diabetes prescribed semaglutide or tirzepatide.
Semaglutide pregnancy case series
A 2026 case series reported outcomes after first-trimester semaglutide exposure in 16 pregnancies. The result is useful but cannot establish safety.
Semaglutide in type 1 diabetes: ADJUST-T1D
ADJUST-T1D found better glucose-and-weight outcomes with semaglutide in selected adults, but it did not test long-term cardiovascular benefit.